Associations of blood homocysteine concentrations in Arab schizophrenic patients

Clinical Biochemistry

Volumn 40, Issue 13-14, 2007, Pages 1026-1031

  Akanji, A O ^a   Ohaeri, J U ^b   Al Shammri, S A ^a   Fatania, H R ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Psychological Medicine Hospital Kuwait   (Kuwait)

Author keywords

Arabs; Disease phenotypes; Homocysteine; Lipoproteins; Oxidative stress; Schizophrenia

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; AGED; AMINO ACID BLOOD LEVEL; ARAB; ARTICLE; AUTOANALYZER; BLOOD SAMPLING; BODY MASS; CHEMICAL PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; HUMAN; IMMUNOASSAY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; QUESTIONNAIRE; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADOLESCENT; ADULT; AGED; ARABS; BODY CONSTITUTION; BODY MASS INDEX; FEMALE; HOMOCYSTEINE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; OXIDATIVE STRESS; QUESTIONNAIRES; SCHIZOPHRENIA; WAIST-HIP RATIO;

EID: 34548127980     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.06.001     Document Type: Article

References (53)

1. el-Hilu S.M., Mousa R., Abdulmalek H., Kamel N., Zohdi M., and al-Aamriti M. Psychiatric morbidity among foreign housemaids in Kuwait. Int. J. Soc. Psychiatry 36 (1990) 291-299
2. al-Ansari E.A., Emara M.M., Mirza I.A., and el-Islam M.F. Schizophrenia in ICD-10: a field trial of suggested diagnostic guidelines. Compr. Psychiatry 30 5 (1989 (Sep.-Oct.)) 416-419
3. Malasi T.H., Mirza I.A., and el-Islam M.F. Factors influencing long-term psychiatric hospitalisation of the elderly in Kuwait. Int. J. Soc. Psychiatry 35 (1989) 223-230
4. Chen J.Y., Hong C.J., Chiu H.J., Lin C.Y., Bai Y.M., Song H.L., et al. Apolipoprotein E genotype and schizophrenia. Neuropsychobiology 39 3 (1999) 141-143
5. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., and Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 149 (2007) 267-271
6. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., and Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res. 57 2 (2002) 247-258
7. Kaul S., Zadeh A.A., and Shah P.K. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J. Am. Coll. Cardiol. 48 5 (2006) 914-923
8. Hankey G.J. Is plasma homocysteine a modifiable risk factor for stroke?. Nat. Clin Pract. Neurol. 2 1 (2006) 26-33
9. Kannel W.B. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40 12 (2005) 1215-1220
10. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., and Ueland P.M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch. Neurol. 55 (1998) 1449-1455
11. McCaddon A., Davies G., Hudson P., Tandy S., and Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 13 (1998) 235-239
12. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346 (2002) 476-483
13. Ramakrishnan S., Sulochana K.N., Lakshmi S., Selvi R., and Angayarkanni N. Biochemistry of homocysteine in health and diseases. Indian J. Biochem. Biophys. 43 (2006) 275-283
14. Regland B., Johansson B.V., Grenfeldt B., Hjelmgren L.T., and Medhus M. Homocystinemia is a common feature of schizophrenia. J. Neural Transm. 100 (1995) 165-169
15. Lerner V., Miodownik C., Kaptsan A., Vishne T., Sela B.A., and Levine J. High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia. J. Clin. Psychiatry 66 (2005) 1558-1563
16. Levine J., Sela B.A., Osher Y., and Belmaker R.H. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog. Neuro-psychopharmacol. Biol. Psychiatry 29 (2005) 1181-1191
17. Levine J., Stahl Z., Ami B., Slava S., Ruderman G.V., and Belmaker R.H. Elevated homocysteine levels in young male patients with schizophrenia. Am. J. Psychiatry 159 (2002) 1790-1792
18. World Health Organization. International statistical classification of diseases and related health problems. 10th Revision. WHO, Geneva. 1992.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Edition. American Psychiatric Association, Washington, DC. 1994.
20. Wing J.K., Babor T., Brugha T., Burke J., Cooper J.E., Giel R., et al. SCAN-Schedules for Clinical Assessment in Neuropsychiatry. Arch. Gen. Psychiatry 47 (1990) 589-593
21. Kay S.R., and Sevy S. Pyramidal model of schizophrenia. Schizophr Bull. 16 (1990) 537-545
22. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) (1981), University of Iowa, Iowa City
23. Friedewald W.T., Levy R.I., and Frederickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
24. Virgos C., Martorell L., Simo J.M., Valero J., Figuera L., Joven J., et al. Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. NeuroReport 10 (1999) 2035-2038
25. Henderson D.C., Copeland P.M., Nguyen D.D., Borba C.P., Cather C., Eden Evins A., et al. Homocysteine level and glucose metabolism in non obese, non-diabetic chronic schizophrenia. Acta Psychiatr. Scand. 113 (2006) 121-125
26. Nevo G.A., Meged S., Sela B.A., Hanoch-Levi A., Hershko R., and Weizman A. Homocysteine levels in adolescent schizophrenia patients. Eur. Neuropsychopharmacol. 16 8 (2006) 588-591
27. Reif A., Schneider M.F., Kamolz S., and Pfuhlmann B. Homocystinemia in psychiatric disorders: association with dementia and depression, but not schizophrenia in female patients. J. Neural Transm. 110 (2003) 1401-1411
28. Goff D.C., Bottiglieri T., Arning E., Shih V., Freudenreich O., Evins A.E., et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am. J. Psychiatry 161 (2004) 1705-1708
29. Applebaum J., Shimon H., Sela B.A., Belmaker R.H., and Levine J. Homocysteine levels in newly admitted schizophrenic patients. J. Psychiatr. Res. 38 (2004) 413-416
30. Brown A.S., and Susser E.S. Homocysteine and schizophrenia: from prenatal to adult life. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 1175-1180
31. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg L.H., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93 (1996) 7-9
32. Diaz-Arrastia R. Hyperhomocystinemia: a new risk factor for Alzheimer disease?. Arch. Neurol. 55 (1998) 1407-1408
33. Picker J.D., and Coyle J.T. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia?. Harv. Rev. Psychiatry 13 (2005) 197-205
34. Stahl Z., Belmaker R.H., Friger M., and Levine J. Nutritional and life style determinants of homocysteine in schizophrenia patients. Eur. Neuropsychopharmacol. 15 (2005) 291-295
35. Lee Y.S., Han D.H., Jeon C.M., Lyoo I.K., Na C., Chae S.L., and Cho S.C. Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients. NeuroReport 17 (2006) 743-746
36. Muntjewerff J.W., Hoogendoorn M.L., Kahn R.S., Sinke R.J., Den Heijer M., Kluijtmans L.A., et al. Homocystinemia, methylenetetrahydrofolate reductase 677TT genotype and the risk for schizophrenia: a Dutch population based case-control study. Am. J. Med. Genet., B Neuropsychiatr. Genet. 135 (2005) 69-72
37. Weisberg I.S., Jacques P.F., Selhub J., Bostom A.G., Chen Z., Curtis Ellison R., et al. The 1298A → C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 156 (2001) 409-415
38. Weisberg I.S., Tran P., Christensen B., Sibani S., and Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab. 64 (1998) 69-172
39. Reif A., Pfuhlmann B., and Lesch K.-P. Homocystinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 1162-1168
40. Vilella E., Virgos C., Murphy M., Martorell L., Valero J., Simó J.M., et al. Further evidence that hyperhomocystinemia and methylenetetra-hydrofolate reductase C677T and A1289C polymorphisms are not risk factors for schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 1169-1174
41. Geisel X.J., Hubner U., Bodis M., Schorr H., Knapp J.P., Obeid R., et al. The role of genetic factors in the development of hyperhomocystinemia. Clin. Chem. Lab. Med. 41 (2003) 1427-1434
42. Almawi W.Y., Finan R.R., Tamim H., Daccache J.L., and Irani-Hakime N. Differences in the frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene among the Lebanese population. Am. J. Hematol. 76 (2004) 85-87
43. Kerkeni M., Addad F., Chauffert M., Myara A., Gerhardt M., Chevenne D., et al. Hyperhomocystinemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann. Clin Biochem. 43 (2006) 200-206
44. Bu R., Gutierrez M.I., Al-Rasheed M., Belgaumi A., and Bhatia K. Variable drug metabolism genes in Arab population. J. Pharmacogenomics 4 4 (2004) 260-266
45. AbuAmero K.K., Wyngaard C.A., and Dzimiri N. Prevalence and role of methylenetetra-hydrofolate reductase 677 C → T and 1298 A → C polymorphisms in coronary artery disease in Arabs. Arch. Pathol. Lab. Med. 127 (2003) 1349-1352
46. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
47. Hagg S., Lindblom Y., Mjorndal T., and Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int. Clin. Psychopharmacol. 21 (2006) 93-98
48. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. J. Heart 150 (2005) 1115-1121
49. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80 (2005) 19-32
50. Kruman I.I., Culmsee C., Chan S.L., Kruman Y., Guo Z., Penix L., et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excito[1] toxicity. J. Neurosci. 20 (2000) 6920-6926
51. Antun F.T., Burnett G.B., Cooper A.J., Daly R.J., Smythies J.R., and Tealley H.K. The effects of l-methionine (without MAOI) in schizophrenia. J. Psychiatr. Res. 8 (1971) 63-71
52. Cohen S.M., Nichols A., Wyatt R., and Pollin W. The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol. Psychiatry 8 (1974) 209-224
53. Pollin W., Cardon P., and Kety S. Effect of amino acid feedings in schizophrenic patients treated with iproniazid. Science 133 (1961) 104-105